Shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) were up 2.5% during trading on Thursday . The company traded as high as $14.40 and last traded at $14.18, with a volume of 125,942 shares. The stock had previously closed at $13.84.

A number of analysts have recently commented on BLCM shares. SunTrust Banks Inc. started coverage on Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $20.00 target price on the stock. Piper Jaffray Cos. reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Saturday, July 9th. Finally, Zacks Investment Research upgraded Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $28.00.

The stock’s 50 day moving average is $13.16 and its 200 day moving average is $11.29. The company’s market capitalization is $371.30 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.07. Equities analysts predict that Bellicum Pharmacueticals Inc. will post ($2.22) earnings per share for the current fiscal year.

In related news, COO Annemarie Moseley sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total value of $325,000.00. Following the completion of the sale, the chief operating officer now owns 18,486 shares in the company, valued at approximately $240,318. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CTO Kevin M. Slawin sold 55,000 shares of the company’s stock in a transaction that occurred on Friday, April 22nd. The shares were sold at an average price of $11.43, for a total transaction of $628,650.00. Following the completion of the sale, the chief technology officer now owns 159,206 shares of the company’s stock, valued at approximately $1,819,724.58. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley boosted its stake in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned approximately 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent quarter.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.